FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

doi:10.1172/JCI75539

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

The Journal of clinical investigation - 1 Sept 2014

Li Shuying S, Gilbert Peter B, Tomaras Georgia D, Kijak Gustavo, Ferrari Guido, Thomas Rasmi, Pyo Chul-Woo, Zolla-Pazner Susan, Montefiori David, Liao Hua-Xin, Nabel Gary, Pinter Abraham, Evans David T, Gottardo Raphael, Dai James Y, Janes Holly, Morris Daryl, Fong Youyi, Edlefsen Paul T, Li Fusheng, Frahm Nicole, Alpert Michael D, Prentice Heather, Rerks-Ngarm Supachai, Pitisuttithum Punnee, Kaewkungwal Jaranit, Nitayaphan Sorachai, Robb Merlin L, O'Connell Robert J, Haynes Barton F, Michael Nelson L, Kim Jerome H, McElrath M Juliana, Geraghty Daniel E

Abstract excerpt

The phase III RV144 HIV-1 vaccine trial estimated vaccine efficacy (VE) to be 31.2%. This trial demonstrated that the presence of HIV-1-specific IgG-binding Abs to envelope (Env) V1V2 inversely correlated with infection risk, while the presence of Env-specific plasma IgA Abs directly correlated with risk of HIV-1 infection. Moreover, Ab-dependent cellular cytotoxicity responses inversely correlated with risk of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to AIDS Vaccines

Share to HIV-1

Share to HIV Antibodies

Share to HIV Envelope Protein gp120

Share to Polymorphism, Single Nucleotide

Share to Receptors, IgG

Share to Vaccination

Source

Open in PubMed Open full text

Identifiers

PMID: 25105367
DOI: 10.1172/JCI75539
PMCID: PMC4151214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.PMID 25105367Read ↗

FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-γ Receptors in Human B Cells.Semantic proximity Read ↗

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.Semantic proximity Read ↗

IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial.Semantic proximity Read ↗

FcγR Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations.Semantic proximity Read ↗

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.Semantic proximity Read ↗

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.Semantic proximity Read ↗

Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.Semantic proximity Read ↗

V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC ActivitySemantic proximity Read ↗

An HIV Vaccine Protective Allele in FCGR2C Associates With Increased Odds of Perinatal HIV Acquisition.Semantic proximity Read ↗

Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.Semantic proximity Read ↗

The changing face of HIV vaccine research.Semantic proximity Read ↗

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.